Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Ripretinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ripretinib is a Small molecule drug targeting PDGFRα x c-Kit, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Ensifentrine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ensifentrine is a Small molecule drug targeting PDE3 x PDE4, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
TET1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for TET1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Paxalisib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Paxalisib is a Small molecule drug targeting Akt x PI3Ks x mTOR, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Sorafenib Tosylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Sorafenib Tosylate is a Small molecule drug targeting BRAF x CRAF x FLT3 x PDGFRβ x RET x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit, at Approved. This 2026 report.
Latest Hotspot
8 min read
Lenvatinib mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Lenvatinib mesylate is a Small molecule drug targeting FGFR1 x FGFR2 x FGFR3 x FGFR4 x PDGFRα x RET x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit, at Approved. This.
Latest Hotspot
8 min read
Fruquintinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Fruquintinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Aflibercept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Aflibercept is a Fc fusion protein targeting PGF x VEGF-A, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
SULT1E1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for SULT1E1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Treprostinil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Treprostinil is a Small molecule drug targeting PGI2 receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Lomitapide Mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Lomitapide Mesylate is a Small molecule drug targeting MTTP, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Bempedoic acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Bempedoic acid is a Small molecule drug targeting ACL, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.